“cost factors for NWBO to file with the FDA appear to be beyond their control and financial capabilities,”
Incorrect . Provide some documentation that a drug with orphan status designation in US has significantly more financial burden for an application to FDA as opposed to MHRA
Market Data 
Markets 
AI
